We don't hear anywhere near enough in the media about the work of commercializing biotech and regenerative medicine, yet this part of the path from laboratory to therapy is just as vital as the initial science. This article from the Miami Herald gives a brief overview of the current state of play for stem cells in the business and venture capital worlds. The short of it would be that many, many people are interested, and see huge potential for investment and profit. Unfortunately, the current regulatory atmosphere presents equally large risks. The current US administration, and other governments overseas, have scared off investment in regenerative medicine. Thus, more time and lives are lost to the monster of politics.